Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG, ODYSSEY OUTCOMES Investigators (2020)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Eur Heart J (in press)
DOI 10.1093/eurheartj/ehaa649, PubMed 33051646

Marciniak TA, Atar D, Serebruany V (2020)
The Perils of Data Sharing, Meta-analyses, and Estimating Rosiglitazone Cardiovascular Risk
Eur Heart J Cardiovasc Pharmacother (in press)
DOI 10.1093/ehjcvp/pvaa109, PubMed 32941601

El Hadidi S, Rosano G, Tamargo J, Agewall S, Drexel H, Kaski JC, Niessner A, Lewis BS, Coats AJS (2020)
Potentially Inappropriate Prescriptions in Heart Failure with Reduced Ejection Fraction (PIP-HFrEF)
Eur Heart J Cardiovasc Pharmacother (in press)
DOI 10.1093/ehjcvp/pvaa108, PubMed 32941594